Adi Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 28-12-2024
- Paid Up Capital ₹ 0.10 M
as on 28-12-2024
- Company Age 22 Year, 6 Months
- Last Filing with ROC 31 Mar 2015
- Open Charges ₹ 5.59 M
as on 28-12-2024
- Revenue -14.77%
(FY 2013)
- Profit -131.26%
(FY 2013)
- Ebitda -14.77%
(FY 2013)
- Net Worth -659.05%
(FY 2013)
- Total Assets -2.65%
(FY 2013)
About Adi Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2015. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.59 M.
Mohan Deo, Vijay Valavalkar, Anand Khadilkar, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24233MH2002PTC136177
- Company No.
136177
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jun 2002
- Date of AGM
30 Sep 2015
- Date of Balance Sheet
31 Mar 2015
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationThane, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Adi Pharma?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohan Deo  | Director | 11-Jun-2002 | Current |
| Vijay Valavalkar | Director | 11-Jun-2002 | Current |
| Anand Khadilkar | Director | 11-Jun-2002 | Current |
| Vinayak Valavalkar | Director | 11-Jun-2002 | Current |
| Sunil Tirodkar | Director | 11-Jun-2002 | Current |
Financial Performance of Adi Pharma.
Adi Pharma Private Limited, for the financial year ended 2013, experienced significant reduction in revenue, with a 14.77% decrease. The company also saw a substantial fall in profitability, with a 131.26% decrease in profit. The company's net worth observed a substantial decline by a decrease of 659.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adi Pharma?
In 2015, Adi Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Dombivli Nagari Sahakari Bank Limited Creation Date: 30 Mar 2010 | ₹3.19 M | Open |
Bank Of Baroda Creation Date: 26 Feb 2004 | ₹2.00 M | Open |
Bank Of Baroda Creation Date: 11 Mar 2003 | ₹0.40 M | Open |
How Many Employees Work at Adi Pharma?
Unlock and access historical data on people associated with Adi Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adi Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adi Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
